dabigatran has been researched along with Disseminated Intravascular Coagulation in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bousounis, A; Ho, WK; Hogan, C; Kanda, GS; Rodrigues, C | 1 |
Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
Ishiura, R; Narushima, M; Yasumoto, A; Yatomi, Y | 1 |
Ardillon, L; Boon, LM; Eeckhoudt, S; Hermans, C; Lambert, C | 1 |
4 other study(ies) available for dabigatran and Disseminated Intravascular Coagulation
Article | Year |
---|---|
Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran.
Topics: Administration, Oral; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Disseminated Intravascular Coagulation; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Partial Thromboplastin Time; Prothrombin Time; Reproducibility of Results; Thrombin; Thrombin Time | 2021 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations.
Topics: Adolescent; Anemia; Antithrombins; Atrial Fibrillation; Dabigatran; Disseminated Intravascular Coagulation; Erythrocyte Transfusion; Female; Humans; Treatment Outcome; Vascular Malformations | 2017 |
Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations.
Topics: Adult; Anticoagulants; Blood Platelets; Dabigatran; Disseminated Intravascular Coagulation; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Platelet Count; Thrombosis; Vascular Malformations | 2016 |